
GSK’s application to expand use of Nucala (mepolizumab) for the treatment of COPD accepted for review by the European ...
Submission based on data from MATINEE trial, which showed a statistically significant and clinically meaningful reduction in the annualised rate of moderate/severe exacerbations with mepolizumab versus placebo Nucala (mepolizumab) could be the first …